AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12883695
Drug: Weight-based dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-based dosing of epoetin alpha (150 IU/kg)
Trial: 2861282
Drug: Triazolam (TZ)
RxNorm normalized name: Triazolam
DrugBank: Triazolam (DB00897)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triazolam (TZ) 0.5 to 3.0 mg
Trial: 2861282
Drug: Pentobarbital (PTB)
RxNorm normalized name: Pentobarbital
DrugBank: Pentobarbital (DB00312)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentobarbital (PTB) 100 to 600 mg
Trial: 10473885
Drug: Hydroxyurea (HU)
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (HU) therapy for 5 months
Trial: 1929683
Drug: Hydrochlorothiazide (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (both doses)
Trial: 7201757
Drug: Tobramycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin (1 mg/kg)
Trial: 7201757
Drug: Gentamicin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin (1 mg/kg)
Trial: 7201757
Drug: Cefazolin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (500 mg)
Trial: 25559818
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of trastuzumab and lapatinib
Trial: 28045953
Drug: Cyclophosphamide (CPM)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (CPM) 750 mg/m2 body surface area
Trial: 21198798
Drug: PCA cream
RxNorm normalized name: lauryl PCA
DrugBank: Pidolic acid (DB03088)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA cream applied twice daily before UV irradiation
Trial: 21198798
Drug: Control cream
RxNorm normalized name: BENZOYL PEROXIDE 3 mg in 60 mL TOPICAL LIQUID [Acnecare Dermacontrol Cream]
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control cream applied twice daily before UV irradiation
Trial: 21198798
Drug: PCA cream
RxNorm normalized name: lauryl PCA
DrugBank: Pidolic acid (DB03088)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA cream applied after UV irradiation
Trial: 21198798
Drug: Control cream
RxNorm normalized name: BENZOYL PEROXIDE 3 mg in 60 mL TOPICAL LIQUID [Acnecare Dermacontrol Cream]
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control cream applied after UV irradiation
Trial: 14689371
Drug: Telmisartan (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (40 mg for the first two weeks, 80 mg for 5.5 months, and 40 mg for the last two weeks)
Trial: 14689371
Drug: Metoprolol (47.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (47.5 mg for two weeks, 95 mg for 5.5 months, and 47.5 mg for the last two weeks)
Trial: 10631628
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg sumatriptan succinate alone
Trial: 10631628
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg sumatriptan succinate with 500 mg naproxen
Trial: 9048267
Drug: β-Blockers (carvedilol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-Blockers (carvedilol and bisoprolol)
Trial: 9048267
Drug: Future studies
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Future studies (β-blocker Evaluation Survival Trial - BEST)
Trial: 27391900
Drug: 9 months
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 9 months of intermittent anti-tuberculous therapy under DOTS (86 women)
Trial: 21415777
Drug: Docetaxel and
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel and cisplatin (DP) chemotherapy
Trial: 21415777
Drug: Mitomycin C,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitomycin C, vindesine, and cisplatin (MVP) chemotherapy
Trial: 12882671
Drug: Intraperitoneal chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal chemotherapy with 50 mg mitomycin bound to 375 mg carbon adsorbent (MMC‐CH)
Trial: 12882671
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (systemic chemotherapy 3 months after operation)
Trial: 7995977
Drug: Alovudine at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alovudine at AUC12s of 50, 100, or 200 ng*h/mL for up to 16 weeks
Trial: 3820493
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1500 mg/d)
Trial: 27189323
Drug: S-1 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 80 mg/m2 twice daily plus nab-paclitaxel 220 mg/m2 on day 1
Trial: 27189323
Drug: S-1 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 80 mg/m2 twice daily plus nab-paclitaxel 260 mg/m2 on day 1
Trial: 27189323
Drug: S-1 and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 and nab-paclitaxel combination therapy
Trial: 21320109
Drug: Carisbamate 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carisbamate 1,200 mg/day
Trial: 21320109
Drug: Combined carisbamate
RxNorm normalized name: Chlorphenesin Carbamate
DrugBank: Chlorphenesin carbamate (DB14656)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined carisbamate doses
Trial: 21320109
Drug: Carisbamate 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carisbamate 1,200 mg
Trial: 21320109
Drug: Carisbamate 800
RxNorm normalized name: Chlorphenesin Carbamate
DrugBank: Chlorphenesin carbamate (DB14656)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carisbamate 800 mg
Trial: 19276857
Drug: 7 g
RxNorm normalized name: Vaporizer 1.7 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 g L-arginine before resistance exercise
Trial: 15020659
Drug: Bicalutamide 80
RxNorm normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bicalutamide 80 mg combined with LHRH agonist
Trial: 31187203
Drug: LHRH agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHRH agonist monotherapy
Trial: 31079973
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus VKA
Trial: 31079973
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and clopidogrel plus VKA
Trial: 31079973
Drug: No antithrombotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antithrombotic medication
Trial: 24736677
Drug: B12 Supplement
RxNorm normalized name: Vitamin B12 supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B12 Supplement (oral cyanocobalamin 6 μg/day)
Trial: 20624510
Drug: Combined exercise
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined exercise and cognitive behavioral therapy (EX/CBT)
Trial: 18923204
Drug: Per-oral endoscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Per-oral endoscopic dilatation alone
Trial: 15565164
Drug: All trans
RxNorm normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All trans retinoic acid (ATRA) and chemotherapy
Trial: 12729868
Drug: Control Therapy
RxNorm normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Therapy (intensive occupational therapy activities)
Trial: 10323627
Drug: Topical placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical placebo (control)
Trial: 6216093
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g mezlocillin three times
Trial: 6216093
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g cefuroxime three times
Trial: 29480965
Drug: Intercostal nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intercostal nerve block (ICNB) treatment (Group B)
Trial: 29480965
Drug: Sufentanil treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil treatment (Group A)
Trial: 25444576
Drug: 10 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g/day soluble milk proteins rich in leucine (PRO)
Trial: 20194853
Drug: DTIC+IFN‐alpha+Talpha1 (3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTIC+IFN‐alpha+Talpha1 (3.2 mg)
Trial: 20194853
Drug: DTIC+Talpha1 (3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTIC+Talpha1 (3.2 mg)
Trial: 20194853
Drug: Talpha1 (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talpha1 (any dosage)
Trial: 12385067
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of sublingual stabilized NADH (n = 18)
Trial: 12385067
Drug: Identical placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo tablets (n = 17)
Trial: 10212076
Drug: Cisapride (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (0.2 mg/kg, 8 hourly)
Trial: 7754011
Drug: Gd-EOB-DTPA at
RxNorm normalized name: Gd-EOB-DTPA
DrugBank: Gadoxetic acid (DB08884)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gd-EOB-DTPA at doses of 10, 25, 50, and 100 mumol/kg
Trial: 2309538
Drug: Fentanyl (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (10 micrograms.kg‐1 loading dose and 2 micrograms.kg‐1 increments)
Trial: 2309538
Drug: Alfentanil (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil (100 micrograms.kg‐1 initial loading dose and either 20 micrograms.kg‐1 increments or 1 microgram.kg‐1.min‐1 continuous infusion)
Trial: 2309538
Drug: Alfentanil (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil (100 micrograms.kg‐1 initial loading dose)
Trial: 25251930
Drug: Rhodiola crenulata/Cordyceps
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhodiola crenulata/Cordyceps sinensis supplementation (1400 mg R + 600 mg C per day)
Trial: 22483761
Drug: 0.18% sodium
RxNorm normalized name: Dextrose 4% and 0.18% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.18% sodium hyaluronate solution (0.18% SH)
Trial: 20447652
Drug: Low-dose quetiapine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose quetiapine (100-400 mg/day)
Trial: 8783319
Drug: Proglumide (cholecystokinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proglumide (cholecystokinin antagonist)
Trial: 3893508
Drug: Ketotifen (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen (1 mg orally)
Trial: 31126574
Drug: Soy milk
RxNorm normalized name: DIMETHICONE 4 g in 100 g CUTANEOUS PATCH [FERMENTED SOY MILK WRINKLE CARE SLEEPING MASK]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy milk (240 ml/day for 8 weeks)
Trial: 25148829
Drug: ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe 10 mg/day + fenofibrate 200 mg/day
Trial: 21801104
Drug: Lidocaine cream
RxNorm normalized name: Neomycin and Polymyxin B Sulfates and Lidocaine Cream
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine cream (4% lidocaine)
Trial: 21801104
Drug: Lidocaine-prilocaine cream
RxNorm normalized name: lidocaine / prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine-prilocaine cream (2.5%)
Trial: 16335883
Drug: Telmisartan 40
RxNorm normalized name: telmisartan 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 40 mg plus HCTZ 12.5 mg (T40/H12.5)
Trial: 16335883
Drug: Telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg plus HCTZ 12.5 mg (T80/H12.5)
Trial: 9865456
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg intravenous dose of methylprednisolone (Phase II)
Trial: 7711991
Drug: sustained-release diltiazem
RxNorm normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sustained-release diltiazem 180 mg
Trial: 7711991
Drug: sustained-release nicardipine
RxNorm normalized name: nicardipine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sustained-release nicardipine 40 mg
Trial: 2403775
Drug: Morphine sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulfate (30 mg, intramuscularly)
Trial: 354483
Drug: tranexamic acid,
RxNorm normalized name: Tranexamic Acid, 650 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tranexamic acid, 6 gm daily for 14 to 21 days
Trial: 354483
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (bedrest, dexamethasone when cerebral edema developed, plus isotonic saline)
Trial: 28533108
Drug: xylazine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: xylazine (1 mg kg−1) and tiletamine–zolazepam (8 mg kg−1) with hyaluronidase (400 IU)
Trial: 28533108
Drug: xylazine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: xylazine (1 mg kg−1) and tiletamine–zolazepam (8 mg kg−1) (control treatment, CON)
Trial: 26385029
Drug: Caffeine 200
RxNorm normalized name: caffeine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 200 mg twice daily
Trial: 25110952
Drug: 6% carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% carbohydrate capsules (CHOc)
Trial: 25110952
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules (PLAc)
Trial: 19320804
Drug: L-arginine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine supplementation during the first 28 days of life
Trial: 17300625
Drug: 0 ml
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 ml of soya milk (0 g of fat)
Trial: 17300625
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of soya milk (0.32 g of fat)
Trial: 17300625
Drug: 40 ml
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 ml of soya milk (1.28 g of fat)
Trial: 17300625
Drug: 150 ml
RxNorm normalized name: REBYOTA 150 ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 ml of soya milk (4.8 g of fat)
Trial: 17300625
Drug: 500 ml
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml of soya milk (16 g of fat)
Trial: 17627399
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment regimens
Trial: 9848038
Drug: CSVTCG receptor
RxNorm normalized name: Toll-like receptor 9
DrugBank: Toll-like receptor 9 (DB15320)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSVTCG receptor
Trial: 28100507
Drug: Iron-supplement bars
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-supplement bars (14 mg Fe/day) for 90 days
Trial: 23011357
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) at a dose of 7.5 mg/week over 12-18 months
Trial: 11448476
Drug: Etretinate (Tigason)
RxNorm normalized name: etretinate
DrugBank: Etretinate (DB00926)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etretinate (Tigason) treatment
Trial: 8368641
Drug: LTD4 inhalation
RxNorm normalized name: LTD4
DrugBank: Leukotriene D4 (DB11858)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LTD4 inhalation
Trial: 8368641
Drug: PAF inhalation
RxNorm normalized name: pafuramidine
DrugBank: Pafuramidine (DB06532)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAF inhalation
Trial: 11693896
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (4 mg) via 15‐minute intravenous infusion
Trial: 11693896
Drug: Pamidronate (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (90 mg) via 2‐hour intravenous infusion
Trial: 11693896
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (4 mg) and pamidronate
Trial: 30802201
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (new tablet)
Trial: 30802201
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (original capsule)
Trial: 30802201
Drug: Both formulations
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both formulations under fed condition
Trial: 24589044
Drug: Octenidine wound
RxNorm normalized name: octenidine
DrugBank: Octenidine (DB12624)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octenidine wound gel plus modern wound-phase-adapted dressings (treatment arm 2)
Trial: 24589044
Drug: Octenidine wound
RxNorm normalized name: octenidine
DrugBank: Octenidine (DB12624)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octenidine wound gel alone (treatment arm 3)
Trial: 24589044
Drug: Modern wound-phase-adapted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modern wound-phase-adapted dressings alone (treatment arm 1)
Trial: 24589044
Drug: Octenidine wound
RxNorm normalized name: octenidine
DrugBank: Octenidine (DB12624)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octenidine wound gel treatment (treatment arms 2 and 3)
Trial: 16080809
Drug: Irbesartan/HCTZ combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan/HCTZ combination tablets (COAPROVEL)
Trial: 12413243
Drug: Experimental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatment 1 (riluzole, dosage not specified)
Trial: 12413243
Drug: Experimental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatment 2 (riluzole, dosage not specified)
Trial: 31852499
Drug: Mass drug
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass drug administration for malaria transmission interruption
Trial: 23357841
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg sirukumab
Trial: 23357841
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg sirukumab
Trial: 23357841
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg sirukumab
Trial: 21258039
Drug: Emulsion combining
RxNorm normalized name: propofol lipid emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emulsion combining glycerol and paraffin applied twice daily for 7 days
Trial: 21258039
Drug: Emulsion alone
RxNorm normalized name: propofol lipid emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emulsion alone (comparator) applied twice daily for 7 days
Trial: 19549643
Drug: General anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anaesthesia PCA with opioids (fentanyl 6 microg ml(‐1) and tramadol 3 mg ml(‐1))
Trial: 15631774
Drug: Neurotropin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurotropin (6 ml, IV, QD for 2 weeks, then 2 tablets, BID for another 2 weeks)
Trial: 15631774
Drug: Methycobal (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methycobal (1 ml, IM, QD for 2 weeks, then 1 tablet TID for another 2 weeks)
Trial: 9210750
Drug: 0.75 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 ml/kg of alcohol
Trial: 8135469
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg Aminoglutethimide (AG) daily
Trial: 8135469
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg Aminoglutethimide (AG) daily
Trial: 8135469
Drug: Cortisone Acetate
RxNorm normalized name: Cortisone Acetate
DrugBank: Cortisone (DB14681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cortisone Acetate (CA) replacement dose 37.5 mg/day orally (used in both groups)
Trial: 3479419
Drug: Oral ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ciprofloxacin 750 mg bid
Trial: 3479419
Drug: Oral ofloxacin
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ofloxacin 400 mg bid
Trial: 31077229
Drug: Central BP-guided
RxNorm normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Central BP-guided treatment
Trial: 25458463
Drug: Inhaled glutathione
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled glutathione (GSH)
Trial: 23785463
Drug: Streptococcus salivarius
RxNorm normalized name: Streptococcus salivarius
DrugBank: Streptococcus salivarius (DB19274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptococcus salivarius M18 (various doses)
Trial: 21961534
Drug: Exercise group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise group (EG, n = 52) - supervised aerobic dance and strength training for 60 minutes, twice per week for a minimum of 12 weeks
Trial: 19100344
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) for 3 months
Trial: 16502768
Drug: EZE/SIMVA 10/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EZE/SIMVA 10/10 mg/mg